Triptans--pivotal event in migraine treatment

• Published in: Acta medica Croatica Vol. 62; no. 2; p. 173
• Main Authors: Lusić, Ivo, Bilić, Ivica
• Format: Journal Article
• Language: Croatian
• Published: Croatia 01-05-2008
• Subjects: Drug Interactions; Humans; Migraine Disorders - drug therapy; Tryptamines - adverse effects; Tryptamines - pharmacokinetics; Tryptamines - therapeutic use
• ISSN: 1330-0164

Introducing serotonin 5-HT1B/1D agonists in the migraine treatment in the early 1990s had for the first time set guidelines for targeting a hypothetic physiologic source of the sequence of events in migraine, and results thus achieved were considerably better than those accomplished with earlier nonselective pharmacological approach. Triptans have revolutionized migraine management and inspired many epidemiological and public health surveys, strengthened efforts in understanding pathophysiology of migraine and initiated synthesis of many similar drugs in the triptan group, the first being sumatriptan. Triptans have risen to a therapeutic challenge posed by migraine, successfully thwarting the cycle of pain. In treating migraine sufferers, physicians can choose among seven triptans with different attributes. Each patient merits individualized approach in the treatment of migraine with triptans. Choosing the right triptan for a given patient is a matter of first matching the appropriate formulation to the patient, then deciding which agent will best meet the patient's needs. This process requires thorough understanding of the patient, careful and accurate assessment of the efficacy of previous medications used in acute care, and analysis of the individual features of the triptans being considered.